Traveler's Diarrhea Clinical Trial
Official title:
Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging Study to Assess the Immunogenicity and Safety of LT Application in Healthy Adults
The main purpose of this study is to evaluate the body's immune response to the LT patch at
different doses.
The secondary purpose of this study is to evaluate the safety of the LT patches at different
doses and the safety of the skin preparation system. Another secondary purpose is to compare
the safety and the body's immune response to LT patches placed on the upper arm versus the
lower back.
This is a randomized, double-blind, placebo-controlled, dose ranging, multicenter study. Subjects will be assigned to one of ten treatment groups and vaccinated according to the study group designation. Treatments will remain the same for first and second vaccinations (alternating left and right sides). ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01208922 -
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
|
Phase 3 | |
Completed |
NCT01142089 -
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
|
Phase 3 | |
Not yet recruiting |
NCT04026984 -
Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
|
Phase 2 | |
Not yet recruiting |
NCT04027894 -
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
|
Phase 2 | |
Completed |
NCT03866291 -
ESBL in Patients Returning to Sweden With Traveller's Diarrhoea
|
||
Completed |
NCT03301103 -
PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli
|
N/A | |
Completed |
NCT01040325 -
Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study
|
Phase 2 | |
Withdrawn |
NCT02736539 -
Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea
|
Phase 3 |